ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ATOS / earnings
QNRX (37) AYTU (27) TXMD (34) IMMP (47) ⌘ Pro Terminal →

Atossa Therapeutics Inc. (ATOS) Next Earnings Date & Expected ±12.5% Move

$2.30 +5.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.32

Atossa Therapeutics Inc. (ATOS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $21.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATOS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.30 (+5.99% 1D, market cap $21.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ATOS ranks #695 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATOS compare to QNRX and AYTU in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $21.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATOS?
▼

Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $104.0M in revenue (+34.5% YoY), -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.32 (+0.89%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$16 Bull$2 Base$2 Bear
📬 FREE ATOS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATOS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY ATOS SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 41 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$2.56-0.8% Next Q
Q2 (-2Q)
38
Grade E$2.54-6.3% Next Q
Q3 (-1Q)
36
Grade E$2.38-3.4% Next Q
Current
33
Grade E$2.30-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATOS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATOS currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.41) and Max Pain ($2.42) forces dealer call-delta covering toward $15.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATOS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ATOS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.29 Expected Swing
$2.01 (-12.5%)Spot $2.30$2.59 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ATOS Quantitative Pre-Earnings Setup: 33/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (33/100)Model Risk Weight (67/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$104.0M-$34.8M-$29.8M52%
FY 20242024-12-31$77.3M-$25.5M-$21.0M52%
FY 20232023-12-31$87.9M-$30.1M-$20.9M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATOS)

  • ✓Walkthrough of ATOS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ATOS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.75%📐 HORIZONTAL RANGE
2026-11-03O $2.23H $2.30L $2.17C $2.30VOL 32.9K
RES: $3.17SUP: $1.67SMA50: $2.41SMA200: $3.88
$10.33$7.99$5.65$3.31$0.97RES $3.17SUP $1.67$2.302026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATOS Butterfly Map → + Track ATOS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +34.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATOS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATOS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ATOS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATOS)

Health Care Rank #695 of 1015 ⚔️ QNRX vs ATOS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATOS vs. QNRX, AYTU, TXMD, IMMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Atossa Therapeutics Inc. (ATOS) ranks #695 by composite RQD confidence (33/100, grade E) and #824 by equity capitalization ($21.7M). Within this direct 5-issuer industry benchmark cohort, ATOS leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ATOS at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ATOS ACTIVE
Atossa Therapeutics Inc.
E 33/100 — — -35.0% +5.99% $21.7M Benchmark Subject
QNRX
Quoin Pharmaceuticals Ltd.
D- 37/100 — — -35.0% -11.45% $21.8M /qnrx-vs-atos →
AYTU
Aytu BioPharma Inc.
E 27/100 — 69.0% -35.0% +0.52% $21.0M /aytu-vs-atos →
TXMD
TherapeuticsMD Inc.
E 34/100 — — -12.9% +0.56% $20.8M /txmd-vs-atos →
IMMP
Immutep Limited
D 47/100 — — — +0.33% $22.6M /immp-vs-atos →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001488039 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atossa Therapeutics Inc. (ATOS) reported GAAP revenue of $104.0M (+34.5% vs. FY2024 revenue of $77.3M , and +18.4% cumulative change since FY2023) , GAAP net income of -$34.8M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (-41.5% YoY). On the balance sheet, ATOS closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $104.0M -$34.8M -$29.8M -$29.8M $47.6M —
FY2024 (FY) 2024-12-31 $77.3M -$25.5M -$21.0M -$21.0M $76.4M —
FY2023 (FY) 2023-12-31 $87.9M -$30.1M -$20.9M -$20.9M — —

3. ATOS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATOS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Atossa Therapeutics Inc. (NASDAQ: ATOS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.30 (+5.99% 1D, market cap $21.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ATOS ranks #695 in composite RQD confidence.

How does ATOS compare to QNRX and AYTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATOS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $21.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, ATOS leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATOS?

Per ATOS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001488039), Atossa Therapeutics Inc. generated $104.0M in revenue (+34.5% YoY), -$34.8M in net income, and -$29.8M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATOS trading relative to its 50-day, 200-day, and 52-week technical levels?

ATOS last traded at $2.30 (+5.99% on volume of 66,005 shares), positioning the stock -4.56% below its 50-day simple moving average ($2.41) and -40.72% below its 200-day simple moving average ($3.88). Across its 52-week range of $1.70 to $14.85, ATOS sits at the 4.6% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.01 to $2.59).

Direct Sub-Reports: ATOS RQD Cockpit ATOS 12M Forecast ATOS Earnings & Move ATOS Dividends & DRIP ATOS Insiders & 13F ATOS Whale Options ATOS Profit Sankey ATOS News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

ATOS — Atossa Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Atossa Therapeutics Inc. (ATOS) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.30 (+5.99% 1D, market capitalization $21.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Atossa Therapeutics Inc. (ATOS) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — for each of the three listed fiscal years, so the company is not generating revenue in the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Atossa Therapeutics Inc. (ATOS) reported $104.0M in annual revenue (up from $77.3M in FY2024, +34.5% YoY) and -$34.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($87.9M revenue, -$30.1M net income) through FY2025, ATOS scaled operating cash flow to -$29.8M and free cash flow to -$29.8M, backed by $47.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.70 – $14.85 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ATOS carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ATOS sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $104.0M and free cash flow of -$29.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ATOS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATOS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Atossa Therapeutics Inc. (ATOS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATOS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATOS Bull vs. Bear Conversation Board — What's Your Call at $2.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATOS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ATOS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.82 (+30.0%)
📌 Pinned Debate

The CVR agreement ties shareholder participation to potential priority review voucher value, a non-operating path to value that the RQD

Here is why I am bullish on ATOS here at $2.17: The CVR agreement ties shareholder participation to potential priority review voucher value, a non-operating path to value that the RQD framework does not capture in its cash-engine score.. Compare ATOS's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.06 are getting bought.

ArenaChamp_24 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.87 (-13.8%)
Spot @ $2.17

With zero reported revenue, FY 2025 free cash flow of -$29.8M, ROIC of -35%, and cash down from $71.1M to $41.3M, the company faces a c

I respect the product at Atossa Therapeutics Inc., but the stock at $2.17 is a different story. With zero reported revenue, FY 2025 free cash flow of -$29.8M, ROIC of -35%, and cash down from $71.1M to $41.3M, the company faces a clear cash-runway question.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%